We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Qiagen Acquires NGS Analysis Software Company Genoox

By LabMedica International staff writers
Posted on 13 May 2025

QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. More...

The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the QIAGEN Digital Insights (QDI) portfolio, strengthening QIAGEN’s leadership in genetic interpretation for clinical genomics applications. Franklin empowers labs to analyze next-generation sequencing (NGS) data – from targeted gene panels to whole exome and genome sequencing (WES/WGS) - and delivers real-time, AI-driven insights to support clinical decision-making. Applications range from diagnosing genetic disorders and informing cancer treatments to supporting family planning decisions.

The platform is currently used by more than 4,000 healthcare organizations in over 50 countries and has powered more than 750,000 case interpretations to date. The acquisition also creates a path to integrate QIAGEN’s genomic content into the Franklin platform that powers the company’s leading QCI Interpret and QCI Precision Insights solutions. These future integrations will expand Franklin’s interpretive power, and in turn improving diagnostic yield, turnaround time and scalability for clinical labs.

“The acquisition of Genoox brings together two complementary strengths to better serve clinical testing laboratories,” said Thierry Bernard, CEO of QIAGEN. “Franklin’s AI-powered solution offers exciting opportunities for labs to rapidly identify the most clinically relevant insights and help improve patient outcomes. Combined with QIAGEN’s trusted clinical knowledge and interpretation tools, the addition of Franklin to our portfolio will enable QIAGEN to better address the challenges of our customers who are seeking easy-to-use, rapid and scalable clinical decision-support solutions.”

“Joining QIAGEN marks a major milestone in our mission to make genomic data more accessible and actionable,” added Amir Trabelsi, Co-founder and CEO of Genoox. “Franklin will benefit from QIAGEN’s global reach and scientific leadership as we scale to support more labs and patients around the world. As part of QIAGEN, we can together drive the next wave of precision medicine.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Glucose Tolerance Test
NERL Trutol
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: INDICAID HPV Urine Test can detect 14 types of high-risk HPV using patented urine DNA concentration technology (Photo courtesy of PHASE Scientific)

World’s First Urine-Based HPV Test to Transform Cervical Cancer Screening

Human papillomavirus (HPV) is a very common sexually transmitted infection (STI) that causes more than 95% of cervical cancer cases. Detection of HPV infections that lead to cellular transformation, followed... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.